NO20002965L - Antihyperlipidemic statin-LP (a) inhibitor combinations - Google Patents

Antihyperlipidemic statin-LP (a) inhibitor combinations

Info

Publication number
NO20002965L
NO20002965L NO20002965A NO20002965A NO20002965L NO 20002965 L NO20002965 L NO 20002965L NO 20002965 A NO20002965 A NO 20002965A NO 20002965 A NO20002965 A NO 20002965A NO 20002965 L NO20002965 L NO 20002965L
Authority
NO
Norway
Prior art keywords
antihyperlipidemic
statin
inhibitor combinations
inhibitor
combinations
Prior art date
Application number
NO20002965A
Other languages
Norwegian (no)
Other versions
NO20002965D0 (en
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Ramharack
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20002965L publication Critical patent/NO20002965L/en
Publication of NO20002965D0 publication Critical patent/NO20002965D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20002965A 1997-12-12 2000-06-09 Antihyperlipidemic statin-LP (a) inhibitor combinations NO20002965D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
PCT/US1998/023480 WO1999030706A1 (en) 1997-12-12 1998-11-04 ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS

Publications (2)

Publication Number Publication Date
NO20002965L true NO20002965L (en) 2000-06-09
NO20002965D0 NO20002965D0 (en) 2000-06-09

Family

ID=22088939

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002965A NO20002965D0 (en) 1997-12-12 2000-06-09 Antihyperlipidemic statin-LP (a) inhibitor combinations

Country Status (14)

Country Link
EP (1) EP1037623A1 (en)
JP (1) JP2003524582A (en)
KR (1) KR20010033017A (en)
AU (2) AU1306099A (en)
BR (1) BR9813539A (en)
CA (1) CA2299397A1 (en)
HU (1) HUP0100349A3 (en)
IL (1) IL134364A0 (en)
IS (1) IS5385A (en)
NO (1) NO20002965D0 (en)
NZ (1) NZ502874A (en)
PL (1) PL343851A1 (en)
WO (1) WO1999030706A1 (en)
ZA (1) ZA9811349B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
EP1076091A1 (en) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
CA2396157A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
AU2001232245A1 (en) * 2000-02-10 2001-08-20 Takeda Chemical Industries Ltd. Tnf- alpha inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
WO1993013801A1 (en) * 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
JPH07505145A (en) * 1992-02-25 1995-06-08 ワーナー−ランバート・コンパニー Cell protection composition and method for producing and using the same
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (en) * 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
CA2251972A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
KR20010033017A (en) 2001-04-25
IS5385A (en) 2000-02-25
NZ502874A (en) 2004-03-26
AU2003244047A1 (en) 2003-09-25
WO1999030706A1 (en) 1999-06-24
IL134364A0 (en) 2001-04-30
CA2299397A1 (en) 1999-06-24
HUP0100349A2 (en) 2001-07-30
JP2003524582A (en) 2003-08-19
HUP0100349A3 (en) 2002-02-28
AU1306099A (en) 1999-07-05
BR9813539A (en) 2000-10-10
NO20002965D0 (en) 2000-06-09
ZA9811349B (en) 1999-06-14
PL343851A1 (en) 2001-09-10
EP1037623A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
ID24931A (en) NITRIL PROVIDED
FI973544A0 (en) Foerfarande Foer att foermedla meddelanden
FI973718A0 (en) Foerbaettrat foerfarande Foer att byta basstation
DK1004669T3 (en) Newly differentiated inhibitor
DK0958287T3 (en) Sulfamidmetalloprotease inhibitors
NO20003256D0 (en) ACE inhibitor-MMP inhibitor combinations
DE69821569D1 (en) tetrahedral
NO20002659D0 (en) thrombin
DE19756119B4 (en) stapler
ID20285A (en) HAND KATROL
FR2768938B1 (en) SNOWSHOE
FR2760375B1 (en) SNOWSHOE
DE69815029D1 (en) stapler
DE69812851D1 (en) stapler
DE59811177D1 (en) A microwave component
NO20002965D0 (en) Antihyperlipidemic statin-LP (a) inhibitor combinations
FI974260A0 (en) Foerfarande Foer att fermerla en quittering till a A-abonnent
NO995005L (en) A new approach
FR2762977B1 (en) EXTENSION TABLE
DE19882544T1 (en) Jojos improvements
DE69805245D1 (en) stapler
FI973568A0 (en) Foerfarande Foer att foerhindra sintring i en virvelbaedd
DE59709933D1 (en) A circuit-board
DE59809440D1 (en) A microwave component
FI954988A0 (en) A circuit

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application